Document is current
Any future updates will be listed below
-
Authors
Merkx, Robin I.J.
Kleinendorst, Simone C.
Rijpkema, Mark
Franssen, Gerben M.
Morgenstern, Alfred
Bruchertseifer, Frank
Wheatcroft, Michael P.
Oosterwijk, Egbert
Mulders, Peter F.A.
Konijnenberg, Mark
Heskamp, Sandra https://orcid.org/0000-0001-7250-0846
-
Funding
Funding for this research was provided by:
Telix Pharmaceuticals Ltd. (Telix Pharmaceuticals Ltd.)
KWF Kankerbestrijding (2019-2, 12567)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (09150172010054)
- License Information
-
More Information
Article History
Received: 2 April 2026
Accepted: 9 July 2026
First Online: 15 July 2026
Declarations
Institutional review board: Animal experiments were approved by the Dutch central committee on animal research and the local ethical committee on animal research (#2015-0071 and #2020-0007).
Competing interests: Michael P. Wheatcroft (Chief Scientist) is an employee of Telix Pharmaceuticals Ltd. The authors declare no conflict of interest. SH, SK, and MPW are inventors on a patent involving the combination of [ 177 Lu]Lu-DOTA-hG250 with immune checkpoint inhibitor therapy. SH is an inventor on a patent involving PMSA-targeting ligands for multimodal applications and has equity interest and is scientific advisor for Aurelius Therapeutics. The other authors declare that they have no competing interests.
